

L Core Project R030D030604

O Details

| Projects | Name | Award | Publications | Repositories | Analytics |
|-----------------|--|--------------|----------------|----------------|--------------|
| 1R03OD030604-01 | Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing | \$297,000.00 | 9 publications | 0 repositories | 0 properties |

Publications

Published works associated with this project.

| ID | Title | Authors | R C R | SJ R | Cita tion s | Cit./ yea r | Journal | Publ ishe d | Updat ed |
|------------|--|----------------------|-------------|---------|-------------------|-------------------|--------------------|-------------------|-------------|
| 35337371 🗹 | Considerations and challenges for sexaware drug repurposing. | Jennifer L Fisher | 1. 38 | 0 | 9 | 4.5 | Biol Sex Differ | 2022 | Dec 28, |

| | | 4 more Brittany N Lasseign e | | | | | | | 2024 (1 week ago) |
|--------------------------------|--|--|----------|---|---|---|----------------------------|------|--|
| 37533331 🗗 | Evaluating cancer cell line and patient- derived xenograft recapitulation of tumor and non-disease | Avery S Williams2 more Brittany N Lasseign e | 0. 92 | 0 | 3 | 3 | Cancer Rep (Hoboken) | 2023 | Dec 29, 2024 (1 week ago) |
| 36602970 🗗 | Ten simple rules for using public biological data for your research. | Vishal H Oza 9 more Brittany N Lasseign e | 0. 54 | 0 | 2 | 2 | PLoS Comput Biol | 2023 | Dec 28, 2024 (1 week ago) |
| 37824797 ② DOI ② | Computational Advancements in Cancer Combination Therapy Prediction. | Victoria L Flanary 3 more Brittany | 0. 4 | 0 | 2 | 2 | JCO Precis Oncol | 2023 | Jan 5, 2025 (3 days ago) |

| | | N Lasseign e | | | | | | | |
|-----------------------------------|--|---|----------|---|---|---|---------|------|--|
| 37217845 🗗 DOI 🗗 | Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and | Elizabeth J Wilk 9 more Brittany N Lasseign e | 0. 34 | 0 | 1 | 1 | Mol Med | 2023 | Dec 29, 2024 (1 week ago) |
| 37090499 乙 | Evaluating cancer cell line and patient- derived xenograft recapitulation of tumor and non-disease | Avery S Williams2 more Brittany N Lasseign e | 0 | 0 | 0 | 0 | bioRxiv | 2023 | Dec 28, 2024 (1 week ago) |
| 37362157 亿 DOI 亿 | Sex-biased gene expression and gene- regulatory networks of sex-biased adverse event drug targets | Jennifer L Fisher 2 more Brittany N Lasseign e | 0 | 0 | 0 | 0 | bioRxiv | 2023 | Dec 29, 2024 (1 week ago) |

| 38167211 🗗 DOI 🗗 | Sex-biased gene expression and gene- regulatory networks of sex-biased adverse event drug targets | Jennifer L Fisher 2 more Brittany N Lasseign e | 0 | 0 | 0 | 0 | BMC Pharmacol Toxicol | 2024 | Dec 28, 2024 (1 week ago) |
|---------------------|--|---|---|---|---|---|-----------------------------|------|--|
| 38531616 🗹 DOI 🗗 | Signature reversion of three disease- associated gene signatures prioritizes cancer drug repurposi | Jennifer L Fisher 7 more Brittany N Lasseign e | 0 | 0 | 0 | 0 | FEBS Open Bio | 2024 | Dec 28, 2024 (1 week ago) |

Notes

RCR Relative Citation Ratio

SJR Scimago Journal Rank

Publications (cumulative)



| Name | Tags | Last Commit | Avg Issue | Avg PR | Languages | License | Readme | Contributing | Dependencies |
|------|------|-------------|-----------|--------|-----------|---------|--------|--------------|--------------|
| | | | | | No data | | | | |

Notes

Repository For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

Closed/Open Resolved/unresolved.

Avg Issue/PR Average time issues/pull requests stay open for before being closed.

Only the main /default branch is considered for metrics like # of commits.

of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

Analytics

Traffic metrics of websites associated with this project.

Notes

Active Users <u>Distinct users who visited the website</u> **?**.

New Users <u>Users who visited the website for the first time</u> **.**

Engaged Sessions <u>Visits that had significant interaction</u> **?**.

Generated on Jan 8, 2025

Developed with support from NIH Award U54 OD036472

[&]quot;Top" metrics are measured by number of engaged sessions.